(c) 2024 PillSync.com

Lithium Carbonate 450 MG Extended Release Oral Tablet

INDICATIONS AND USAGE Lithium Carbonate Extended-Release Tablets is indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness and possibly hostility. When given to a patient experiencing a manic episode, Lithium Carbonate Extended-Release Tablets may produce a normalization of symptomatology within 1 to 3 weeks.

rising pharmaceuticals, inc.


4 years ago ROUND WHITE P 450 Lithium Carbonate 450 MG Extended Release Oral Tablet

ROUND WHITE P 450

4 years ago ROUND WHITE P 450 Lithium Carbonate 450 MG Extended Release Oral Tablet

P 450 ROUND WHITE

HOW SUPPLIED

LITHIUM CARBONATE Extended-Release Tablets 450 mg are supplied as white to off white round tablets scored on one side and engraved with P; 450 on the other side. NDC 64980-278-01: Bottle of 100 Tablets Storage Condition: Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Manufactured by: Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.), Mumbai 400 030, India Distributed by: Rising Pharmaceuticals, Inc. East Brunswick, NJ 08816 1-866-562-4597 134449 Revised: Jul. 2022


More pills like ROUND P 450












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site